FOCUS ON DELI FOCUS ON DELIVERY VERY Merck KGaA, Darm stadt, Germ - PowerPoint PPT Presentation

FOCUS ON DELI FOCUS ON DELIVERY VERY Merck KGaA, Darm stadt, Germ any Q3 2 0 1 7 results Marcus Kuhnert, CFO Udit Batra, CEO Life Science November 9, 2017

Dis isclaim imer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any misconceptions of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. 2

Disclaim er Cautionary Note Regarding Forw ard-Looking Statem ents and financial indicators This comm unication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such statements. Risks and uncertainties include, but are not limited to: the risks of more restrictive regulatory requirements regarding drug pricing, reimbursement and approval; the risk of stricter regulations for the manufacture, testing and marketing of products; the risk of destabilization of political systems and the establishment of trade barriers; the risk of a changing marketing environment for multiple sclerosis products in the European Union; the risk of greater competitive pressure due to biosimilars; the risks of research and development; the risks of discontinuing development projects and regulatory approval of developed medicines; the risk of a temporary ban on products/ production facilities or of non-registration of products due to non-compliance with quality standards; the risk of an import ban on products to the United States due to an FDA warning letter; the risks of dependency on suppliers; risks due to product-related crime and espionage; risks in relation to the use of financial instruments; liquidity risks; counterparty risks; market risks; risks of impairment on balance sheet items; risks from pension obligations; risks from product-related and patent law disputes; risks from antitrust law proceedings; risks from drug pricing by the divested Generics Group; risks in human resources; risks from e-crime and cyber attacks; risks due to failure of business-critical information technology applications or to failure of data center capacity; environmental and safety risks; unanticipated contract or regulatory issues; a potential downgrade in the rating of the indebtedness of Merck KGaA, Darm stadt, Germany; downward pressure on the common stock price of Merck KGaA, Darmstadt, Germany and its impact on goodwill impairment evaluations; the impact of future regulatory or legislative actions; and the risks and uncertainties detailed by Sigma-Aldrich Corporation (“Sigma-Aldrich”) with respect to its business as described in its reports and documents filed with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere, including the Report on Risks and Opportunities Section of the most recent annual report and quarterly report of Merck KGaA, Darmstadt, Germany, and the Risk Factors section of Sigma-Aldrich’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements made in this communication are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developm ents anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward- looking statement, whether as a result of new information, future developments or otherwise. This quarterly presentation contains certain financial indicators such as EBITDA pre exceptionals, net financial debt and earnings per share pre exceptionals, which are not defined by International Financial Reporting Standards (IFRS). These financial indicators should not be taken into account in order to assess the performance of Merck KGaA, Darmstadt, Germany in isolation or used as an alternative to the financial indicators presented in the consolidated financial statements and determined in accordance with IFRS. The figures presented in this quarterly statement have been rounded. This may lead to individual values not adding up to the totals presented. 3

Agenda Executive sum m ary Financial overview Guidance 4

EXECUTI CUTIVE S VE SUMMARY ARY

Highlights Healthcare – pipeline progressing; initial launches of Mavenclad & Bavencio in Europe Life Science – solid organic growth amid unfavorable mix effect from softer key accounts Operations Performance Materials – strong growth of non-LC businesses; LC normalization continues Organic sales growth of 4.2% ; EBITDA pre down 8.3% to €1,076 m Deleveraging on track, net debt/ EBITDA pre reduced to 2.3x Financials EBITDA pre guidance confirmed despite FX headwinds 6

I nvestm ents in Healthcare and softness in Liquid Crystals burden EBI TDA pre Q3 2017 YoY net sales •Healthcare reflects strong growth in General Medicine, Consumer Health and Fertility Organic Currency Portfolio Total •Solid organic growth in Life Science driven Healthcare -1.2% 5.8% -3.4% 1 .2 % by all businesses Life Science 0.4% 4.8% -3.9% 1 .3 % •Organic growth of ICM 1 , Pigments and OLED is outweighed by ongoing market share Performance Materials -1.5% -3.8% 0.0% -5 .3 % normalization in Liquid Crystals •FX headwinds across all businesses Group -0.4% 0 .1 % 4.2% -3.7% •Healthcare contains investments in Q3 YoY EBITDA pre contributors [ € m] M&S and R&D, partially offset by milestone payments for Bavencio 1,174 -113 + 46 1,076 -33 + 2 •Life Science reflects organic growth offset by negative business mix and FX •Performance Materials lower due to LC normalization, usual price declines and FX Q3 2016 Healthcare Life Science Performance Corporate & Q3 2017 •CO contains FX hedging gains and Materials Other (CO) LTIP 2 benefits 1 I ntegrated Circuit Materials; 2 Long Term I ncentive Plan 7 Totals may not add up due to rounding

Organic grow th in all regions Regional breakdown of net sales [ € m] Regional organic development Europe •Growth in Europe reflects solid demand in + 1 .2 % org. Life Science, almost offset by competition for Rebif, Erbitux and Gonal-f 30% •North America benefits from Life Science growth and Bavencio more than offsetting North America ongoing Rebif decline + 0 .7 % Q3 2017 org. •Strong growth in APAC driven by Net sales: General Medicine, Fertility and Life Science 33% €3,727m outweighing LC normalization 25% Asia-Pacific + 7 .2 % org. •Very strong performance in LATAM and MEA across all major businesses 8% 4% Latin America Middle East & Africa + 9 .2 % + 1 5 .5 % org. org. 8

FI FINAN NANCIAL OVERV OVERVIEW

Q3 2 0 1 7 : Overview of key figures Key figures Comments Δ Q3 2016 Q3 2017 [ €m] •EBITDA pre decline reflects investments in Healthcare and ongoing LC market Net sales 3,724 3 ,7 2 7 0.1% share normalization -8.3% EBITDA pre 1.174 1 ,0 7 6 •EPS pre down due to lower EBITDA pre 31.5% 28.9% Margin (in % of net sales) •Lower operating cash flow driven by 1.70 1 .5 1 -11.2% lower profit & changes in working capital EPS pre •Net financial debt benefits from healthy 7 5 8 -29.0% Operating cash flow 1,067 cash flow and Biosimilars divestment •Working capital reflects increased Δ Dec. 31, 2016 Sept. 30, 2017 [ €m] receivables in Healthcare, higher inventories in all businesses -8.9% Net financial debt 11,513 1 0 ,4 8 3 •Higher headcount related to growth 7.7% Working capital 3,486 3 ,7 5 5 initiatives in Healthcare and Life Science 50,414 5 2 ,8 4 3 4.8% Employees 10 Totals may not add up due to rounding

Reported figures reflect divestm ent of Biosim ilars business Reported results Comments Δ Q3 2016 Q3 2017 [ €m] •EBIT up due to Biosimilars divestment, EBIT 676 despite lower EBITDA pre 9 0 1 33.3% •Lower effective tax rate reflects Financial result -67 -2.1% -6 5 divestment of Biosimilars business Profit before tax 609 8 3 6 37.2% 25.6% Income tax -149 -1 8 7 Effective tax rate (% ) 24.4% 2 2 .4 % Net income 457 41.1% 6 4 5 1.05 EPS (€) 1 .4 8 41.0% 11 Totals may not add up due to rounding